MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

BioNTech SE ADR

Closed

SectorHealthcare

91.9 -1.48

Overview

Share price change

24h

Current

Min

89.96

Max

93.69

Key metrics

By Trading Economics

Income

143M

301M

Sales

-55M

1.2B

EPS

1.08

Profit margin

25.311

Employees

6,772

EBITDA

253M

464M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+54.57% upside

Dividends

By Dow Jones

Next Earnings

5 May 2025

Market Stats

By TradingEconomics

Market Cap

-3.3B

23B

Previous open

93.38

Previous close

91.9

News Sentiment

By Acuity

57%

43%

326 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

BioNTech SE ADR Chart

Past performance is not a reliable indicator of future results.

Related News

4 Feb 2025, 18:52 UTC

Major Market Movers

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

15 Nov 2024, 10:28 UTC

Major Market Movers

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

6 May 2024, 11:27 UTC

Earnings

BioNTech Swings to Net Loss on Lower Covid Vaccine Sales

15 Nov 2024, 11:14 UTC

Market Talk

U.S. Vaccine Stocks Fall After Trump Picks Vaccine Skeptic RFK Jr as Health Department Head-- Market Talk

15 Nov 2024, 10:34 UTC

Market Talk

Vaccine Sector Sell-Off Looks Overdone -- Market Talk

5 Aug 2024, 10:02 UTC

Earnings

BioNTech Sees 2024 R&D Expenses EUR2.4B-EUR2.6B >BNTX

5 Aug 2024, 10:01 UTC

Earnings

BioNTech Backs 2024 View of Rev EUR2.5B-EUR3.1B >BNTX

5 Aug 2024, 10:01 UTC

Earnings

BioNTech: Invested EUR525.6M, or About 90% of 2Q R&D Spend, in Non-Covid-19 Related Activities >BNTX

5 Aug 2024, 10:00 UTC

Earnings

BioNTech 2Q-End Cash, Equivalents, Security Investments EUR18.5 Billion >BNTX

5 Aug 2024, 09:59 UTC

Earnings

BioNTech 2Q Loss EUR807.8M >BNTX

5 Aug 2024, 09:59 UTC

Earnings

BioNTech 2Q Loss/Shr EUR3.36 >BNTX

5 Aug 2024, 09:59 UTC

Earnings

BioNTech 2Q Rev EUR128.7M >BNTX

6 May 2024, 20:15 UTC

Earnings

BioNTech Lifts As Covid Sales Plummet With 90% Of Revenue Still To Come -- IBD

6 May 2024, 10:47 UTC

Earnings

BioNTech Sees FY24 Rev EUR2.5B-EUR3.1B >BNTX

6 May 2024, 10:46 UTC

Earnings

Correct: BioNTech 1Q Loss/Shr EUR1.31 >BNTX

6 May 2024, 10:46 UTC

Earnings

Correct: BioNTech 1Q Loss EUR315.1M >BNTX

6 May 2024, 10:46 UTC

Earnings

Correct: BioNTech 1Q Rev EUR187.6M >BNTX

6 May 2024, 10:45 UTC

Earnings

BioNTech 1Q Rev $187.6M >BNTX

6 May 2024, 10:45 UTC

Earnings

BioNTech 1Q Loss $315.1M >BNTX

6 May 2024, 10:45 UTC

Earnings

BioNTech 1Q Loss/Shr $1.31 >BNTX

Peer Comparison

Price change

BioNTech SE ADR Forecast

Price Target

By TipRanks

54.57% upside

12 Months Forecast

Average 139.56 USD  54.57%

High 171 USD

Low 110 USD

Based on 17 Wall Street analysts offering 12 month price targets forBioNTech SE ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

17 ratings

14

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

87.605 / 95.61Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Strong Bearish Evidence

Sentiment

By Acuity

326 / 386 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac